Quote:

---

Ask Ohm what the odds of success are in Brazil, this time.

---

After getting burned last time by having everything bad that could happen, happening, I won't put a number on current trials. I will say that with the current protocol and a competent CRO we are significantly de-risked.

What could go wrong is skew, very unlikely with Israelita handling the trials. With separate severe and critical trials no chance of it tilting to a lesser severity. No chance of improper dosing in critical.

In severe I would have preferred to see 700mg across all doses just as a precaution. The justification of dosages because of overlap seems correct and they must have the trial data to support it so that shouldn't be a problem.

There could be problems that come completely out of left field like a super-variant that just kills everybody but highly unlikely. The main variable left would be quality of care. Poor quality of care would actual enhance leronlimab's numbers so that would not be an issue.